Combined epithelial marker analysis of tumour budding in stage II colorectal cancer. (29th November 2018)

• Record Type: Journal Article
• Authors: Slik, Khadija; Blom, Sami; Turkki, Riku; Välimäki, Katja; Kurki, Samu; Mustonen, Harri; Haglund, Caj; Carpén, Olli; Kallioniemi, Olli; Korkeila, Eija; Sundström, Jari; Pellinen, Teijo
• Is Part Of: Journal of pathology. Volume 5:Number 1(2019)
• Page Start: 63
• Page End: 78
• Publication Date: 2018-11-29
• Subjects: tumour budding -- colorectal cancer -- multiplex immunohistochemistry -- digital pathology -- integrin β4 -- epithelial‐to‐mesenchymal transition -- prognostics; Pathology -- Periodicals; Diagnosis, Laboratory -- Periodicals; 616.07
• DOI: 10.1002/cjp2.119
• Languages: English
• ISSNs: 2056-4538

Abstract

Abstract: Tumour budding predicts survival of stage II colorectal cancer (CRC) and has been suggested to be associated with epithelial‐to‐mesenchymal transition (EMT). However, the underlying molecular changes of tumour budding remain poorly understood. Here, we performed multiplex immunohistochemistry (mIHC) to phenotypically profile tumours using known EMT‐associated markers: E‐cadherin (adherence junctions), integrin β4 (ITGB4; basement membrane), ZO‐1 (tight junctions), and pan‐cytokeratin. A subpopulation of patients showed high ITGB4 expression in tumour buds, and this coincided with a switch of ITGB4 localisation from the basal membrane of intact epithelium to the cytoplasm of budding cells. Digital image analysis demonstrated that tumour budding with high ITGB4 expression in tissue microarray (TMA) cores correlated with tumour budding assessed from haematoxylin and eosin (H&E) whole sections and independently predicted poor disease‐specific survival in two independent stage II CRC cohorts (hazard ratio [HR] = 4.50 (95% confidence interval [CI] = 1.50–13.5), n = 232; HR = 3.52 (95% CI = 1.30–9.53), n = 72). Furthermore, digitally obtained ITGB4‐high bud count in random TMA cores was better associated with survival outcome than visual tumour bud count in corresponding H&E‐stained samples. In summary, the mIHC‐based phenotypic profiling of human tumour tissue shows strong potential for the molecular characterisation of tumour biology and for the discovery of novel prognostic biomarkers.